• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cachexia, Sarcopenia and Muscle >Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia
【24h】

Biomarkers of sarcopenia in clinical trials—recommendations from the International Working Group on Sarcopenia

机译：少肌症的生物标志物在临床试验中—国际少肌症工作组的建议

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AbstractSarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7–8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.
机译：摘要少肌症是与年龄相关的骨骼肌下降，与老年人相关的临床和社会经济负面结果相关。对这一现象的研究以及预防/治疗策略的发展代表了公共卫生的重点。本文件报告了2011年6月7日至8日在法国图卢兹举行的国际少视症工作组（由老年学者和来自学术界和工业界的科学家组成的工作组）最近会议的结果。这次会议的重点是获取有关可用于肌肉减少症临床试验的当前可用生物标记（功能，生物学或影像学相关）的知识，并被认为是评估年龄相关的骨骼肌修饰的最可靠，最有前途的。还讨论并最终确定了有关评估老年人骨骼肌衰老的具体建议和关于少肌症研究的最佳方法设计。尽管对骨骼肌衰退的研究仍处于非常初步的阶段，但通过更好地了解和治疗这种状况而获得的潜在巨大益处应鼓励对肌肉减少症的研究。但是，合理的不确定性（源于探索新领域和科学进步的指数加速）要求对这一主题采取谨慎而全面的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号